GLP-1 receptor agonists produce major weight loss for most people - one study found an average reduction of about one-quarter of body weight - but 10-15% of users lose little or no weight. Scientists are now trying to explain that failure rate by pinpointing the biological and behavioral factors that blunt response. The goal is to turn those explanations into actionable strategies: ways to predict who will respond, how to tailor treatment, and what alternative or combination therapies to offer non-responders.
Work so far focuses on measurable differences in genetics, gut microbiomes, sex and hormone status, brain circuitry that governs appetite and reward, and drug exposure or adherence. Early genetic and neurobiology studies identify candidate genes and circuits that modulate appetite-suppressing effects; microbiome and metabolic studies suggest gut-driven variation in drug action. Clinicians and drug developers are testing biomarkers, dose adjustments, dual or alternative agonists, and adjunct approaches aimed at the compensatory mechanisms that resist weight loss. Pinning down these specific mechanisms promises more precise prescriptions, new targets for drugs, and personalized weight-loss regimens for those who currently fail to benefit.
Summary generated by AI from the linked article. hn.today is not affiliated with Hacker News or Y Combinator.